Jianyou Pharma 2026 H1 Revenue RMB1.926B, Net Profit Down 34.48%
Jianyou Pharmaceutical (Jianyou Pharma) reported a 2.71% year-on-year decline in first-half 2026 revenue to RMB1.926 billion, while net profit attributable to shareholders fell 34.48% to RMB188 million. Basic earnings per share stood at RMB0.12. The company attributed the profit drop to higher operating costs from increased sales volumes and rising sales expenses for new product launches and market promotion.
Jianyou Pharmaceutical disclosed its 2026 semi-annual report. In the first half of the year, the company achieved operating revenue of RMB1.926 billion, down 2.71% year on year; net profit attributable to shareholders of the listed company was RMB188 million, down 34.48% year on year; basic earnings per share was RMB0.12.
During the reporting period, the company's formulation business revenue achieved scale growth, but with the increase in sales volume, operating costs such as raw materials and manufacturing increased correspondingly. At the same time, the company stepped up market deployment for new products, with increased investment in new product promotion and market publicity, leading to higher related selling expenses. These factors collectively caused the company's profitability to decline year on year.